Can MacroGenics Turn Gilead Sciences' $10M Milestone Into a Major Pipeline Catalyst?
The recent decision by Gilead Sciences to exercise its option to license a preclinical bispecific program from MacroGenics has injected new life into the struggling biotech.
The milestone payment of $10 million, while modest for Gilead, is crucial validation and non dilutive capital for MacroGenics.